Haebe, S.* ; Keay, W.* ; Alig, S.* ; Mohr, A.-W. ; Martin, L.K. ; Heide, M.* ; Secci, R.* ; Krebs, S.* ; Blum, H.* ; Moosmann, A.* ; Louissaint, A.* ; Weinstock, D.M.* ; Thoene, S.* ; von Bergwelt-Baildon, M.* ; Ruland, J.* ; Bararia, D.* ; Weigert, O.*
The molecular ontogeny of follicular lymphoma: Gene mutations succeeding the BCL2 translocation define common precursor cells.
Br. J. Haematol., DOI: 10.1111/bjh.17990 (2021)
Relapsed follicular lymphoma (FL) can arise from common progenitor cells (CPCs). Conceptually, CPC-defining mutations are somatic alterations shared by the initial and relapsed tumours, mostly B-cell leukaemia/lymphoma 2 (BCL2)/immunoglobulin heavy locus (IGH) translocations and other recurrent gene mutations. Through complementary approaches for highly sensitive mutation detection, we do not find CPC-defining mutations in highly purified BCL2/IGH-negative haematopoietic progenitor cells in clinical remission samples from three patients with relapsed FL. Instead, we find cells harbouring the same BCL2/IGH translocation but lacking CREB binding protein (CREBBP), lysine methyltransferase 2D (KMT2D) and other recurrent gene mutations. Thus, (i) the BCL2/IGH translocation can precede CPC-defining mutations in human FL, and (ii) BCL2/IGH-translocated cells can persist in clinical remission.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Lymphoma ; Molecular Ontogeny ; Common Progenitor Cells ; Bcl2 ; Igh Translocation ; Minimal Residual Disease; Stem-cell; B-cells
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2021
Prepublished im Jahr
HGF-Berichtsjahr
2021
ISSN (print) / ISBN
0007-1048
e-ISSN
1365-2141
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band:
Heft:
Seiten:
Artikelnummer:
Supplement:
Reihe
Verlag
Wiley
Verlagsort
111 River St, Hoboken 07030-5774, Nj Usa
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Immune Response and Infection
PSP-Element(e)
G-501500-001
Förderungen
ProjektDEAL
Max-Eder Program of the Deutsche Krebshilfe
Dr Mildred Scheel postdoctoral fellowship of the Deutsche Krebshilfe
National Cancer Institute (NCI)
Follicular Lymphoma Foundation
European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme
Deutsche Forschungsgemeinschaft (DFG, German Research foundation)
Copyright
Erfassungsdatum
2022-01-28